Patents by Inventor Kirsten Raun

Kirsten Raun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amylin and calcitonin receptor agonist
    Patent number: 10174082
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: January 8, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Novel Amylin And Calcitonin Receptor Agonist
    Publication number: 20170145059
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Amylin and calcitonin receptor agonist
    Patent number: 9593149
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: March 14, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Kirsten Raun
  • Regulation of food preference using GLP-1 agonists
    Patent number: 9486504
    Abstract: GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 8, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Raun, Pia Von Voss, Liselotte Bjerre Knudsen, Kjell Malmlöf
  • Novel Amylin And Calcitonin Receptor Agonist
    Publication number: 20160272683
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 22, 2016
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • GLP-1 Agonists
    Publication number: 20150038417
    Abstract: A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist.
    Type: Application
    Filed: December 10, 2012
    Publication date: February 5, 2015
    Inventor: Kirsten Raun
  • Derivatives of CGRP
    Patent number: 8835379
    Abstract: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 16, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Anette Sams Nielsen, Thomas Kruse, Janos Tibor Kodra, Jesper F. Lau, Jacob Kofoed, Kirsten Raun, Cecilia Nilsson
  • LEPTIN DERIVATIVES
    Publication number: 20140018290
    Abstract: The invention relates to Leptin derivatives, compositions and therapeutic use there-of.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 16, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Kilian Waldemar Conde-Frieboes, Johan Fredrik Paulsson, Kirsten Raun
  • Derivatives of CGRP
    Publication number: 20120245083
    Abstract: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.
    Type: Application
    Filed: October 27, 2010
    Publication date: September 27, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Anette Sams Nielsen, Thomas Kruse, Janos Tibor Kodra, Jesper F. Lau, Jacob Kofoed, Kirsten Raun, Cecilia Nilsson
  • Regulation of Food Preference Using GLP-1 Agonists
    Publication number: 20100222277
    Abstract: GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: NOVO NORDISK A/S
    Inventors: KIRSTEN RAUN, PIA VON VOSS, LISELOTTE BJERRE KNUDSEN, KJELL MALMLÖF
  • Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
    Publication number: 20100022446
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: January 17, 2008
    Publication date: January 28, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Schjellerup Wulff, Kirsten Raun, Birgit Sehested Hansen
  • Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
    Publication number: 20090149512
    Abstract: Ghrelin antagonists can be used for the treatment of certain CNS disorders. For example, certain oxadiazoles, preferably such being ghrelin antagonists, can be used to treat obesity, e.g., drug-induced obesity.
    Type: Application
    Filed: May 13, 2005
    Publication date: June 11, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Kirsten Raun, Lotte Bjerre Knudsen, Elene J.Hother Carlsen, Bernd Peschke, Jesper Lau, Karin Rimwall
  • Use of Growth Hormone in Treatment of Long-Bone Fractures
    Publication number: 20080119819
    Abstract: A method for promoting healing of a long-bone fracture in a human subject in need thereof comprises administration, e.g. by subcutaneous injection, of human growth hormone (hGH), or an analogue or derivative thereof, to the subject in a dose equivalent to 10 45-100 ?g hGH/kg body weight/day.
    Type: Application
    Filed: April 29, 2005
    Publication date: May 22, 2008
    Inventors: Michael Hojby, Mapoko Mbelenge IIondo, Kirsten Raun
  • Regulation of food preference using GLP-1 agonists
    Publication number: 20070082844
    Abstract: GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono-and di-saccharides together constitute a large proportion of the total amount of carbohydrates.
    Type: Application
    Filed: June 7, 2006
    Publication date: April 12, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Kirsten Raun, Pia Von Voss, Liselotte Knudsen, Kjell Malmlof
  • Growth Hormone Secretagogue Receptor Type 1A Agonists
    Publication number: 20070066540
    Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
    Type: Application
    Filed: June 19, 2006
    Publication date: March 22, 2007
    Inventors: Maibritt Andersen, Birgit Hansen, Kirsten Raun, Soren Tullin, Lars Thim
  • Identification and Use of Growth Hormone Secretagogue Receptor Type 1A Antagonists
    Publication number: 20070060609
    Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
    Type: Application
    Filed: June 19, 2006
    Publication date: March 15, 2007
    Inventors: Maibritt Anderson, Birgit Hansen, Kirsten Raun, Soren Tullin, Lars Thim
  • Identification and use of growth hormone secretagogue receptor type 1A antagonists
    Publication number: 20060039862
    Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
    Type: Application
    Filed: June 10, 2005
    Publication date: February 23, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Maibritt Andersen, Birgit Hansen, Kirsten Raun, Soren Tullin, Lars Thim
  • Use of compounds for the regulation of food intake
    Publication number: 20040063636
    Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
    Type: Application
    Filed: August 27, 2003
    Publication date: April 1, 2004
    Inventors: Maibritt Bansholm Andersen, Birgit Sehested Hansen, Kirsten Raun, Soren Tullin, Lars Thim
  • Use of compounds for the regulation of food intake
    Publication number: 20010020012
    Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.
    Type: Application
    Filed: January 29, 2001
    Publication date: September 6, 2001
    Inventors: Maibritt Bansholm Andersen, Birgit Sehested Hansen, Kirsten Raun, Soren Tullin, Lars Thim